Malaria vaccine live unattenuated plus chloroquine - Sanaria
Alternative Names: PfSPZ Challenge plus chloroquine; PfSPZ CVac; PfSPZ malaria vaccine live unattenuated plus chloroquine - Sanaria; Plasmodium falciparum sporozoite vaccine live unattenuated plus chloroquine - SanariaLatest Information Update: 25 Dec 2024
Price :
$50 *
At a glance
- Originator Sanaria
- Developer National Institute of Allergy and Infectious Diseases; Sanaria; University of Tubingen
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Falciparum malaria
Most Recent Events
- 23 May 2024 The US FDA places a clinical hold on PfSPZ Challenge (NCT04280692)
- 23 May 2024 University of Oxford in collaboration with Sanaria suspends the phase I/II CHMI-TransMod trial in Falciparum malaria (In volunteers, Prevention) in Kenya (IV) (NCT04280692)
- 22 Aug 2022 Phase-I/II clinical trials in Falciparum malaria (In volunteers, Prevention) in Kenya (IV) (NCT04280692)